Neoadjuvant chemotherapy in head and neck cancer: Should it be revisited?

Specenier, Pol; Vermorken, Jan B.

doi:10.1016/j.canlet.2007.06.015

Cited by 38 publications

(19 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NACT is used as it helps in control of micrometastasis and might downstage the tumor and hence making the lesions operable. [6,7] In a study by Paccagnella, [8] the 5 and 10 year survival data of operable and inoperable patients showed benefit in terms of reduction in distant metastasis in those who received induction chemotherapy followed by radiotherapy when compared with radiotherapy alone. However, none of the randomized trial has shown any benefit in the overall survival.…”

Section: Discussionmentioning

confidence: 98%

Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…NACT is used keeping in mind that it could help in control of micro metastasis and might downstage the tumour and hence making lesions operable. 8,9 Only two positive phase III trials of induction chemotherapy have been published to date: the Gruppo di Studio sui Tumori della Testa e del Collo, which showed a survival benefit for patients who were considered ineligible for resection and the Groupe d'Etude des Tumeurs de la Teˆte et du Cou, which was limited to oropharynx cancer. Thus, the benefit of induction chemotherapy in clinical practice compared with the present standard CT/RT is unclear.…”

Section: Discussionmentioning

confidence: 99%

The effect of induction chemotherapy followed by chemoradiotherapy in advanced head and neck cancer: a prospective study

et al. 2014

View full text Add to dashboard Cite

INTRODUCTIONHead and neck cancers constitute 5% of all cancers worldwide and in the Indian population, it accounts above 50% of all malignant tumours. Most of the patients present with locally or locoregionally advanced disease. As a result of their location, these tumors can cause varying degree of functional and cosmetic deformity that are often exacerbated by cancer treatment.Larynx preservation trial 1991, 1 the non-surgical organ preservation through the radiation and chemotherapy entered the main stream. Since then the most significant advances in the treatment of head and neck tumours have been the development of altered fractionation schedules ABSTRACT Background: Objective of current study was to observe the local control, progression free survival and organ preservation for locally advanced head and neck cancer by using induction Chemotherapy followed by concurrent chemoradiotherapy. Methods: 102 patients enrolled in this study with stage III-IVB of head & neck cancer. Patients were assessed and treated by faculty of the department as per NCCN guidelines. Group A patients received three courses of cisplatin (100mg/m 2 ) and paclitaxel (175mg/m 2 ) at every 21 days interval followed by concurrent chemoradiothearpy with cisplatin 30mg/m 2 on weekly basis while group B received only concurrent chemoradiothearpy. Radiotherapy consisted of total dose up to 66-70 Gy. by conventional fractionation schedule. Results: From August 2011 to July 2013, total 102 patients have completed 14 months of follow up after completing definitive treatment group A : 48 and group B: 54 patients. Response evaluation was done after one and half months of completion of chemoradiotherapy in both arms. Complete response rate was 60.42% and 38.88 % in study and control arm respectively while partial response was 72.92% and 55.56%. Most common grade III or IV toxicity was mucositis in group A and skin reaction in control arm. At a median follow-up 13 months the median progression free survival in group A was 11.5 months and 9 months in group B. Conclusion: Response to induction chemotherapy was useful as predictive factor for ultimate outcome and progression free survival. But our study shows statistically significant improvement in complete response rate in group A as compared to group B (p<0.05). Our induction chemotherapy with two-drug regimen followed by concurrent chemoradiotherapy was well tolerated with manageable toxicity and good locoregional control.

show abstract

“…The patient and, when applicable, legal guardian should participate in the therapeutic decision after explanation of the risks and benefits of treatment alternatives. Treatment selection depends primarily on the location and stage of the tumor, general status and acceptance of the patient (Singh and Pfister, 2008;Mehanna et al, 2008;Specenier and Vermorken, 2007;Sanabria et al, 2007). The surgery is indicated only in the cases of small easily removable lesions (Gulac et al, 2007).…”

Section: Introductionmentioning

confidence: 99%